Apigenin's Modulation of Doxorubicin Efficacy in Breast Cancer.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
01 Jun 2024
Historique:
received: 05 04 2024
revised: 16 05 2024
accepted: 23 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

Apigenin, a naturally derived flavonoid, is increasingly being acknowledged for its potential therapeutic applications, especially in oncology. This research explores apigenin's capacity to modulate cancer cell viability, emphasizing its roles beyond its minimal antioxidant activity attributed to its basic molecular structure devoid of hydroxyl groups. We investigated apigenin's effects on two breast cancer cell lines, estrogen-dependent MCF-7 and non-estrogen-dependent MDA-MB-231 cells. Our findings reveal that apigenin exerts a dose-dependent cytotoxic and anti-migratory impact on these cells. Interestingly, both apigenin and doxorubicin-a standard chemotherapeutic agent-induced lipid droplet accumulation in a dose-dependent manner in MDA-MB-231 cells. This phenomenon was absent in MCF-7 cells and not evident when doxorubicin and apigenin were used concurrently, suggesting distinct cellular responses to these treatments that imply that their synergistic effects might be mediated through mechanisms unrelated to lipid metabolism. A further chemoinformatics analysis indicated that apigenin and doxorubicin might interact primarily at the level of ATP-binding cassette (ABC) transporter proteins, with potential indirect influences from the AKT and MYC signaling pathways. These results highlight the importance of understanding the nuanced interactions between apigenin and conventional chemotherapeutic drugs, as they could lead to more effective strategies for cancer treatment. This study underscores apigenin's potential as a modulator of cancer cell dynamics through mechanisms independent of its direct antioxidant effects, thereby contributing to the development of flavonoid-based adjunct therapies in cancer management.

Identifiants

pubmed: 38893482
pii: molecules29112603
doi: 10.3390/molecules29112603
pii:
doi:

Substances chimiques

Apigenin 7V515PI7F6
Doxorubicin 80168379AG

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Science and Higher Education
ID : No. 0233/DIA/2019/48

Auteurs

Aleksandra Golonko (A)

Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.

Adam Jan Olichwier (AJ)

Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.

Agata Szklaruk (A)

Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.

Adam Paszko (A)

Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.

Renata Świsłocka (R)

Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, 15-351 Bialystok, Poland.

Łukasz Szczerbiński (Ł)

Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.

Włodzimierz Lewandowski (W)

Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, 15-351 Bialystok, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH